Raymond James Trust N.A. Has $3.25 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Raymond James Trust N.A. lessened its stake in Edwards Lifesciences Co. (NYSE:EW) by 7.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 49,249 shares of the medical research company’s stock after selling 4,037 shares during the quarter. Raymond James Trust N.A.’s holdings in Edwards Lifesciences were worth $3,250,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in EW. LRI Investments LLC bought a new position in Edwards Lifesciences in the 1st quarter worth approximately $67,000. Lazard Asset Management LLC raised its position in shares of Edwards Lifesciences by 89.6% during the first quarter. Lazard Asset Management LLC now owns 93,629 shares of the medical research company’s stock worth $8,946,000 after acquiring an additional 44,257 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Edwards Lifesciences by 57.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock valued at $622,695,000 after acquiring an additional 2,390,137 shares during the period. Bellevue Group AG boosted its holdings in Edwards Lifesciences by 8.3% in the first quarter. Bellevue Group AG now owns 1,103,136 shares of the medical research company’s stock valued at $105,416,000 after acquiring an additional 84,138 shares during the last quarter. Finally, Kennedy Capital Management LLC acquired a new stake in Edwards Lifesciences in the first quarter worth about $2,440,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other news, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. This represents a 11.18 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total transaction of $347,550.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,262,521.36. This represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 40,000 shares of company stock valued at $2,657,000. Corporate insiders own 1.29% of the company’s stock.

Wall Street Analysts Forecast Growth

EW has been the topic of a number of research reports. JPMorgan Chase & Co. upped their target price on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Wells Fargo & Company reduced their price objective on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. Evercore ISI dropped their target price on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. Morgan Stanley restated an “equal weight” rating and issued a $70.00 price target on shares of Edwards Lifesciences in a research report on Friday, October 11th. Finally, The Goldman Sachs Group dropped their price objective on Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating for the company in a report on Friday, July 26th. Seventeen research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $75.67.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $70.49 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a market cap of $41.58 billion, a price-to-earnings ratio of 10.17, a price-to-earnings-growth ratio of 3.95 and a beta of 1.12. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The stock’s 50-day moving average is $67.70 and its 200-day moving average is $75.73.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the prior year, the firm posted $0.59 EPS. The business’s revenue was up 8.9% on a year-over-year basis. Equities analysts predict that Edwards Lifesciences Co. will post 2.57 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.